CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Since androgen signaling plays a pivotal role in the proliferation and metastasis of prostate cancer, androgen deprivation therapy (ADT) or castration therapy is considered the backbone of treatment for newly diagnosed metastatic prostate cancer. However, almost all men experience disease progressio...
Main Authors: | Anitha B. Alex, Sumanta K. Pal, Neeraj Agarwal |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016642370 |
Similar Items
-
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
by: Naoki Terada, et al.
Published: (2017-08-01) -
Checkpoint inhibitors in lung cancer: latest developments and clinical potential
by: Gustavo Schvartsman, et al.
Published: (2016-11-01) -
Advances in thyroid cancer treatment: latest evidence and clinical potential
by: T. Alonso-Gordoa, et al.
Published: (2015-01-01) -
Nivolumab in melanoma: latest evidence and clinical potential
by: Douglas B. Johnson, et al.
Published: (2015-03-01) -
Nivolumab in NSCLC: latest evidence and clinical potential
by: Raghav Sundar, et al.
Published: (2015-03-01)